Boston Scientific 8-K 2007
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 1, 2007
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)
Registrant’s telephone number, including area code: (508) 650-8000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On March 5, 2007, Boston Scientific Corporation (the “Company”) issued a press release announcing a request for information received on March 1, 2007, from Representative Henry A. Waxman, Chairman of the Committee on Oversight and Government Reform of the U.S. House of Representatives, about the Company’s TAXUS® paclitaxel-eluting coronary stents. A copy of the press release is furnished with this report as Exhibit 99.1. A form of the request letter is furnished with this report as Exhibit 99.2.
The information in this Current Report on Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INDEX TO EXHIBITS